Intraday Performance and Price Movement
On 11 Feb 2026, Windlas Biotech Ltd’s share price fell sharply, registering a day change of -7.76%. The stock’s intraday low of Rs 782 marked an 8.11% drop from its prior levels, signalling notable price pressure throughout the trading session. This decline contrasts starkly with the Sensex’s near-flat performance, which recorded a marginal change of -0.03% and traded at 84,252.60 points after opening flat with a gain of 65.23 points.
The stock’s underperformance was also evident relative to its sector peers, as it lagged the Pharmaceuticals & Biotechnology sector by 8.7% on the day. This marks the second consecutive day of losses for Windlas Biotech, with a cumulative decline of 10.64% over this period, underscoring sustained selling momentum.
Technical Indicators and Moving Averages
From a technical standpoint, Windlas Biotech is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning suggests a bearish trend in the short to long term, with the stock failing to find support at these commonly watched technical levels. The breach of these averages often signals caution among traders and can contribute to further downside pressure.
Market Context and Broader Index Trends
Despite the weakness in Windlas Biotech, the broader market environment remains relatively stable. The Sensex is trading close to its 52-week high of 86,159.02, currently just 2.26% below that peak. The index has been on a three-week consecutive rise, gaining 3.33% during this period, and is supported by a bullish technical setup where the 50-day moving average remains above the 200-day moving average. This divergence between the stock’s performance and the broader market highlights company-specific pressures rather than a general market downturn.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Comparative Performance Over Multiple Timeframes
Examining Windlas Biotech’s performance across various time horizons reveals a mixed picture. Over the past one month, the stock has gained 4.49%, outperforming the Sensex’s 0.84% rise during the same period. However, this short-term gain is offset by declines in other intervals: a 6.90% drop over three months, a 6.94% fall over one year, and an 8.19% loss in the past week. Year-to-date, the stock is down 1.26%, slightly worse than the Sensex’s 1.10% decline.
Longer-term returns show a more positive trend, with Windlas Biotech delivering a 211.01% gain over three years, significantly outpacing the Sensex’s 38.89% rise. However, the stock’s five- and ten-year returns are flat at 0.00%, compared to the Sensex’s 63.55% and 267.21% gains respectively, indicating periods of stagnation in the past decade.
Mojo Score and Analyst Ratings
Windlas Biotech currently holds a Mojo Score of 40.0, categorised as a Sell grade. This rating was downgraded from Hold on 4 Feb 2026, reflecting a reassessment of the stock’s fundamentals and momentum. The company’s market capitalisation grade stands at 3, indicating a smaller market cap relative to larger peers in the Pharmaceuticals & Biotechnology sector. These metrics align with the recent price weakness and suggest ongoing challenges in regaining investor confidence.
Sector and Industry Considerations
The Pharmaceuticals & Biotechnology sector has shown resilience in recent weeks, supported by steady demand and innovation trends. However, Windlas Biotech’s underperformance relative to its sector peers indicates company-specific factors influencing its share price. The stock’s decline of 7.76% on a day when the sector remained relatively stable points to immediate pressures that may include profit-taking or reassessment of recent developments.
Windlas Biotech Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Immediate Pressures
The stock’s sharp intraday decline and failure to hold above key moving averages suggest that selling pressure remains elevated. The two-day consecutive fall and cumulative 10.64% loss over this period highlight a cautious stance among market participants. While the broader market and sector indices maintain a positive or stable trajectory, Windlas Biotech’s price action indicates that it is currently facing headwinds that are weighing on its valuation.
Investors monitoring the stock will note the divergence from the Sensex’s ongoing three-week rally and the sector’s relative steadiness. This divergence underscores the importance of company-specific factors in driving the stock’s performance on 11 Feb 2026.
Conclusion
Windlas Biotech Ltd’s intraday low of Rs 782 on 11 Feb 2026 reflects significant price pressure amid a market environment that remains broadly positive. The stock’s underperformance relative to the sector and benchmark indices, combined with its technical positioning below all major moving averages, signals ongoing challenges in the near term. The downgrade to a Sell grade and a Mojo Score of 40.0 further contextualise the current market sentiment. While the broader Pharmaceuticals & Biotechnology sector continues to show resilience, Windlas Biotech’s recent price action suggests that it is navigating a period of subdued investor confidence and immediate selling pressure.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
